Perhaps despite not having the cache of ‘guaranteed-weight-loss’, ‘quit smoking now’ or even a cure-all for cancer, pharmaceuticals for the treatment of rare diseases can be an attractive investment strategy.
Amicus Therapeutics is the developer of small molecule, orally administered … Continue Reading
As we round out our series on private equity investing in dialysis, we note an emergence in overseas dialysis investing by U.S. investors. Our blog typically focuses on U.S. investing but can’t help but note the interest in overseas … Continue Reading
Part II of our series on private equity investing in dialysis discusses other dialysis companies backed by private equity and highlights some key considerations for investors and companies.
Funded in 2000, U.S. Renal Care (USRC), is another dialysis company … Continue Reading